By Bachem AG
To get in touch with Bachem reshapes Corporate Executive Committee, simply fill out the form below.
Subscribe to Supplier
Bachem reshapes Corporate Executive Committee
Bubendorf, Switzerland: – Pioneering peptide producer Bachem today announced that current Chief Operations Officer (COO) and Corporate Executive Committee member Thomas Meier will become the company’s new CEO, replacing Dr. Thomas Früh.
Dr. Früh is stepping down as CEO on health grounds effective January 1, 2020, but will continue to serve the company in a corporate services role.
The Board of Directors has appointed Roland Schürmann to the Corporate Executive Committee as the new Group COO.
Thomas Meier was born in 1968 in Schaffhausen. He joined Bachem AG in 1993 as Team Leader Active Pharmaceutical Ingredients, after which he held various management posts in the United States, Switzerland and Europe. He has been Group COO and a member of the Corporate Executive Committee since 2019. Thomas Meier has a university of applied sciences degree in chemistry. In addition, he graduated from the part-time Swiss Technical Association degree course in Industrial Engineering and completed the Advanced Management Program at INSEAD Business School, Fontainebleau/Paris.
Roland Schürmann was born in Zug in 1964. After completing his education, he worked as a chemical laboratory technician at Ciba-Geigy AG and as a production chemist at F. Hoffmann-La Roche Ltd from 1984 to 1997. After holding various management positions at Siegfried Ltd in Zofingen, Switzerland, he became the company’s Head of Chemical Production in 2004. He moved to the Bachem Group in 2016 and is currently site manager at Bachem Americas, Inc. in Torrance, California. Roland Schürmann has a university of applied sciences degree in chemistry and is currently completing the Advanced Management Program at INSEAD Business School, Fontainebleau/Paris.
Dr. Kuno Sommer, Chairman of Bachem’s Board of Directors, remarked: “We very much regret the reasons that have led to this unscheduled management change, but would like to thank Thomas Früh for his many years of outstanding service to the Bachem Group. In over 26 years with Bachem, during which he has held various roles, including that of CEO since 2012, he has been a key contributor to the company’s success. We are delighted that we can continue to count on his valuable input and experience.”
“In Thomas Meier we have found an extremely experienced and professional successor from within our own ranks to lead the Corporate Executive Committee. His many years with the Bachem Group guarantee a smooth handover and continuity in this important role,” said Dr. Sommer.
“At a time when we are experiencing strong growth, we are also delighted to have found in Roland Schürmann a dynamic individual with an excellent track record to take on the challenging task of COO. The new Corporate Executive Committee line-up will thus still have all the experience and skills needed to seamlessly continue our Bachem success story,” Dr. Sommer concluded.
The Bachem Group is the world’s only full service provider of peptides and provides a full range of other services to the pharma and biotech industries.
Under its banner Pioneering Partner for Peptides, Bachem specializes in the process development and manufacture of peptides and complex organic molecules as active pharmaceutical ingredients (APIs).
A comprehensive catalog of innovative biochemicals for research and exclusive custom syntheses for research labs complete its service portfolio.
Headquartered in Switzerland with subsidiaries in Europe, the US and Asia, the group has a global reach and shows total commitment to quality, innovation and partnership to its customers worldwide.
Bachem prioritizes continuous investment in R&D on chemistries and technologies as crucial for future success. Its ever-increasing knowledge of complex proteins and peptides derives from ongoing research in proteomics, as well as progress in mass spectrometry, synthesis and ligation technologies, complemented by collaboration with external research institutions.
Bachem has six production sites in the U.S. and in Europe along with research level production and full cGMP manufacturing facilities on both continents. These provide capacity to produce APIs, key intermediates, small molecule generics and new chemical entities (NCEs).